| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Miguel A Zamora-Ursulo, Job Perez-Becerra, Luis A Tellez, Nadia Saderi, Luis Carrillo-Rei. Reversal of pathological motor behavior in a model of Parkinson's disease by striatal dopamine uncaging. PloS one. vol 18. issue 8. 2023-08-20. PMID:37594935. |
we conclude that optical delivery of dopamine in the striatum resembles the motor effects induced by systemic injection of dopaminergic agonists in unilateral dopamine-depleted mice. |
2023-08-20 |
2023-09-07 |
mouse |
| Linlin Wang, Qing Dan, Bingxuan Xu, Yun Chen, Tingting Zhen. Research progress on gas signal molecular therapy for Parkinson's disease. Open life sciences. vol 18. issue 1. 2023-08-17. PMID:37588999. |
among the pathological manifestations is the progressive degeneration of the nigrostriatal dopaminergic pathway, leading to massive loss of neurons in the substantia nigra pars compacta and dopamine (da) depletion. |
2023-08-17 |
2023-09-07 |
Not clear |
| Justine H Liang, Viktor Akhanov, Anthony Ho, Mohamed Tawfik, Shane P D'Souza, Morven A Cameron, Richard A Lang, Melanie A Samue. Dopamine signaling from ganglion cells directs layer-specific angiogenesis in the retina. Current biology : CB. 2023-08-12. PMID:37572663. |
dopamine production by canonical dopaminergic amacrine interneurons is dispensable for these events. |
2023-08-12 |
2023-08-16 |
Not clear |
| Yasemin Baranoglu Kilinc, Ibrahim Ethem Torun, Erkan Kilin. D2 dopamine receptor-mediated mechanisms of dopaminergic system modulation in in vivo and in vitro experimental models of migraine. The European journal of neuroscience. 2023-08-04. PMID:37539658. |
d2 dopamine receptor-mediated mechanisms of dopaminergic system modulation in in vivo and in vitro experimental models of migraine. |
2023-08-04 |
2023-08-14 |
rat |
| Rubina Roy, Rajib Paul, Pallab Bhattacharya, Anupom Bora. Combating Dopaminergic Neurodegeneration in Parkinson's Disease through Nanovesicle Technology. ACS chemical neuroscience. 2023-08-03. PMID:37534999. |
parkinson's disease (pd) is characterized by dopaminergic neurodegeneration, resulting in dopamine depletion and motor behavior deficits. |
2023-08-03 |
2023-08-14 |
Not clear |
| Deepika Suri, Giulia Zanni, Darshini Mahadevia, Nao Chuhma, Rinki Saha, Stephen Spivack, Nicolò Pini, Gregory S Stevens, Annette Ziolkowski-Blake, Eleanor H Simpson, Peter Balsam, Stephen Rayport, Mark S Ansorg. Dopamine transporter blockade during adolescence increases adult dopamine function, impulsivity, and aggression. Molecular psychiatry. 2023-08-02. PMID:37532798. |
lastly, using optogenetics to drive dopamine neurons, we find that increased vta but not snc dopaminergic activity mimics the increase in impulsive behavior in the go/nogo task observed after adolescent dat blockade. |
2023-08-02 |
2023-08-14 |
mouse |
| Emil Wärnberg, Arvind Kuma. Feasibility of dopamine as a vector-valued feedback signal in the basal ganglia. Proceedings of the National Academy of Sciences of the United States of America. vol 120. issue 32. 2023-08-01. PMID:37527344. |
inspired by the recent observations that besides rpe, the firing rates of midbrain dopaminergic neurons correlate with motor and cognitive variables, we propose a model in which dopamine signal in the striatum carries a vector-valued error feedback signal (a loss gradient) instead of a homogeneous scalar error (a loss). |
2023-08-01 |
2023-08-14 |
Not clear |
| Can Tao, Guang-Wei Zhang, Junxiang J Huang, Zhong Li, Huizhong W Tao, Li I Zhan. The medial preoptic area mediates depressive-like behaviors induced by ovarian hormone withdrawal through distinct GABAergic projections. Nature neuroscience. 2023-07-31. PMID:37524978. |
these projections enhance activity of dopaminergic neurons in the vta and serotonergic neurons in the dorsal raphe, respectively, with increased release of dopamine and serotonin, possibly through disinhibition mechanisms. |
2023-07-31 |
2023-08-14 |
mouse |
| Rohit Bhatt, Devendra Vaishnav, Vishal Airao, Tejas Sharma, Mahesh Rachamalla, Shalini Mani, Ashish Kumar Gupta, Vijay Upadhye, Saurabh Kumar Jha, Niraj Kumar Jha, Sachin Parma. Neuroprotective potential of saroglitazar in 6-OHDA induced Parkinson's disease in rats. Chemical biology & drug design. 2023-07-30. PMID:37518817. |
degeneration of dopaminergic neurons resulted in reduced dopamine turnover, consequently induced behavioural abnormalities in rats. |
2023-07-30 |
2023-08-14 |
rat |
| Chao Wang, Cheng Zhou, Tao Guo, Yeerfan Jiaerken, Siyu Yang, Xiaopei Xu, Ling Hu, Peiyu Huang, Xiaojun Xu, Minming Zhan. Current coffee consumption is associated with decreased striatal dopamine transporter availability in Parkinson's disease patients and healthy controls. BMC medicine. vol 21. issue 1. 2023-07-25. PMID:37491235. |
we therefore aim to investigate the role of coffee consumption in nigrostriatal dopaminergic neurodegeneration using dopamine transporter (dat) imaging in pd and healthy controls (hc). |
2023-07-25 |
2023-08-14 |
Not clear |
| Ricardo J Ramírez-Carreto, Víctor J Zaldívar-Machorro, Dafne J Pérez-Ramírez, Blanca E Rodríguez-López, Claudia Meza, Esperanza García, Abel Santamaría, Anahí Chavarrí. Oral Administration of Silybin Protects Against MPTP-Induced Neurotoxicity by Reducing Pro-inflammatory Cytokines and Preserving BDNF Levels in Mice. Molecular neurobiology. 2023-07-22. PMID:37480498. |
both exert neuroprotective effects, preserving dopamine levels and dopaminergic neurons when administered in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp) mouse pd model, being probably sb the potential therapeutic molecule behind this effect. |
2023-07-22 |
2023-08-14 |
mouse |
| Robert B Kargb. Microbiome-Gut-Brain Axis Modulation: New Approaches in Treatment of Parkinson's Disease and Amyotrophic Lateral Sclerosis. ACS medicinal chemistry letters. vol 14. issue 7. 2023-07-19. PMID:37465304. |
parkinson's disease (pd) is a neurodegenerative movement disorder characterized by symptoms like resting tremor, rigidity, bradykinesia, and postural instability, mainly due to dopamine depletion and degeneration of dopaminergic neurons. |
2023-07-19 |
2023-08-14 |
Not clear |
| Haoran Peng, Siyuan Chen, Shaopu Wu, Xiaoxue Shi, Jianjun Ma, Hongqi Yang, Xue L. Alpha-synuclein in skin as a high-quality biomarker for Parkinson's disease. Journal of the neurological sciences. vol 451. 2023-07-16. PMID:37454572. |
parkinson's disease (pd), the most common neurological motor system disorder, which characterised by the irreversible loss of dopaminergic neurones in the substantia nigra pars compacta, and leads to the deficiency of dopamine in the striatum. |
2023-07-16 |
2023-08-14 |
human |
| Yiming Wang, Yun Xia, Liang Kou, Sijia Yin, Xiaosa Chi, Jingwen Li, Yadi Sun, Jiawei Wu, Qiulu Zhou, Wenkai Zou, Zongjie Jin, Jinsha Huang, Nian Xiong, Tao Wan. Astrocyte-to-neuron reprogramming and crosstalk in the treatment of Parkinson's disease. Neurobiology of disease. 2023-07-11. PMID:37433411. |
the primary pathological features include a reduction in the number of dopaminergic neurons in the substantia nigra and decrease in dopamine levels in the nigrostriatal pathway. |
2023-07-11 |
2023-08-14 |
human |
| Meghan L Bucher, Amy R Dunn, Joshua M Bradner, Kristen Stout Egerton, James P Burkett, Michelle A Johnson, Gary W Mille. Synaptic vesicle glycoprotein 2C enhances vesicular storage of dopamine and counters dopaminergic toxicity. bioRxiv : the preprint server for biology. 2023-07-10. PMID:37425736. |
synaptic vesicle glycoprotein 2c enhances vesicular storage of dopamine and counters dopaminergic toxicity. |
2023-07-10 |
2023-08-14 |
mouse |
| Harry Costello, Anette-Eleonore Schrag, Robert Howard, Jonathan P Roise. Dissociable effects of dopaminergic medications on depression symptom dimensions in Parkinson's disease. medRxiv : the preprint server for health sciences. 2023-07-10. PMID:37425947. |
loss of dopaminergic innervation of the striatum is associated with emergence of motivational symptoms in pd, and mood fluctuations correlate with dopamine availability. |
2023-07-10 |
2023-08-14 |
Not clear |
| Harry Costello, Anette-Eleonore Schrag, Robert Howard, Jonathan P Roise. Dissociable effects of dopaminergic medications on depression symptom dimensions in Parkinson's disease. medRxiv : the preprint server for health sciences. 2023-07-10. PMID:37425947. |
accordingly, optimising dopaminergic treatment for pd can improve depressive symptoms, and dopamine agonists have shown promising effects in improving apathy. |
2023-07-10 |
2023-08-14 |
Not clear |
| Xu Cao, Zhong-Rui Du, Xin Liu, Xiong Wang, Chong Li, Sai-Nan Zhou, Jia-Rui Liu, Ping-Yi Xu, Jun-Li Ye, Qing Zhao, Fang Zhao, Ka-Hing Wong, Xiao-Li Don. Low and high doses of oral maslinic acid protect against Parkinson's disease via distinct gut microbiota-related mechanisms. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 165. 2023-07-07. PMID:37418977. |
the present study found both low and high dose ma treatment significantly prevented dopaminergic neuronal loss in a classical chronic pd mouse model by ameliorating motor functions and improving tyrosine hydroxylase expressions in the substantia nigra pars compacta (snpc) and increasing dopamine and its metabolite homovanillic acid levels in the striatum. |
2023-07-07 |
2023-08-14 |
mouse |
| Pepin Marshal. Finding an Optimal Level of GDNF Overexpression: Insights from Dopamine Cycling. Cellular and molecular neurobiology. 2023-07-06. PMID:37410316. |
the basic research literature on dopaminergic effects of gdnf in animal models is reviewed, concluding that a twofold increase in natively expressing cells increases dopamine turnover and maximises neuroprotective and beneficial motor effects whilst minimising hyperdopaminergia and other side-effects. |
2023-07-06 |
2023-08-14 |
human |
| Jie Sun, Xiao-Min Lin, Dan-Hua Lu, Meng Wang, Kun Li, Sheng-Rong Li, Zheng-Qiu Li, Cheng-Jun Zhu, Zhi-Min Zhang, Chang-Yu Yan, Ming-Hai Pan, Hai-Biao Gong, Jing-Cheng Feng, Yun-Feng Cao, Feng Huang, Wan-Yang Sun, Hiroshi Kurihara, Yi-Fang Li, Wen-Jun Duan, Gen-Long Jiao, Li Zhang, Rong-Rong H. Midbrain dopamine oxidation links ubiquitination of glutathione peroxidase 4 to ferroptosis of dopaminergic neurons. The Journal of clinical investigation. vol 133. issue 13. 2023-07-03. PMID:37395283. |
midbrain dopamine oxidation links ubiquitination of glutathione peroxidase 4 to ferroptosis of dopaminergic neurons. |
2023-07-03 |
2023-08-14 |
Not clear |